Trial reportScience (New York, N.Y.)2015
Dengue viruses cluster antigenically but not as discrete serotypes.
Abstract readClinical Trial
In one paragraph
Trial report in Science (New York, N.Y.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 149 papers.
0numbers the graph read from it
0cells of the map it votes in
149citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
149 citing papers in PubMed.
- Analysis of Neutralizing Antibodies as a Correlate of Instantaneous Risk of Hospitalized Dengue in Placebo Recipients of Dengue Vaccine Efficacy Trials.The Journal of infectious diseases · 2022Trial
- Analyzing the Human Serum Antibody Responses to a Live Attenuated Tetravalent Dengue Vaccine Candidate.The Journal of infectious diseases · 2018Trial
- Signatures of the neutralizing dengue virus-reactive memory B cell repertoire identified by multiplexed envelope dimer probes.medRxiv : the preprint server for health sciences · 2026Article
- Dengue vaccines: The role of a correlate of protection in evaluating vaccine safety and risk.Vaccine · 2026Article
- From promise to pitfalls: immunological lessons from dengue vaccines and their implications.NPJ vaccines · 2026Review
- Dengue Dilemma: Navigating Cross-Reactivity and Immune Challenges.Current topics in microbiology and immunology · 2026Review
- Unexpected diversification of DENV2 genotype III in Colombia: New Insights and application of the globalized nomenclature.PloS one · 2026Article
- Characterization of Serotype-Specific Dengue Virus T-Cell Inhibition.The Journal of infectious diseases · 2025Article
- Targeted Lymph Node Immunization with Serotype-Specific Dengue VLP Vaccines Enhances Antibody Avidity and Specificity.Vaccines · 2025Article
- CDC dengue typing kit fails to detect dengue virus 2 sylvatic genotype.Journal of clinical microbiology · 2025Article
- Topolow: a mapping algorithm for antigenic cross-reactivity and binding affinity assays.Bioinformatics (Oxford, England) · 2025Article
- Emergence of Dengue Virus Serotypes 1 and 3 in Mahottari and Adjacent Areas of Southern Nepal.Pathogens (Basel, Switzerland) · 2025Article
- Modeling Intraday Aedes-human exposure dynamics enhances dengue risk prediction.Scientific reports · 2025Article
- Assessing the global dengue burden: Incidence, mortality, and disability trends over three decades.PLoS neglected tropical diseases · 2025Observational
- Immunity to Non-Dengue Flaviviruses Impacts Dengue Virus Immunoglobulin G Enzyme-Linked Immunosorbent Assay Specificity in Cambodia.The Journal of infectious diseases · 2025Observational
- Molecular Epidemiology of Dengue Viruses in Lao People's Democratic Republic, 2020-2023.Microorganisms · 2025Article
- Enhancing surveillance for dengue fever in Oyo State, Nigeria - a one health approach.One health outlook · 2025Article
- The pre- and post-COVID-19 pandemic dengue fever patterns in southeastern coastal China in 2019 and 2024: molecular evolution and strain replacement.Frontiers in microbiology · 2025Article
- Factors determining the outcomes of immune imprinting after repeated orthoflavivirus infections.Frontiers in immunology · 2025Review
- Differential Transcriptional Landscape of Vero Cells During Dengue Virus 2 Infection in the Presence of Sinococuline.Microorganisms · 2024Article
89 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Leah C KatzelnickCenter for Pathogen Evolution, Department of Zoology, University of Cambridge, Downing Street, Cambridge CB2 3EJ, UK. World Health Organization (WHO) Collaborating Center for Modeling, Evolution, and Control of Emerging Infectious Diseases, Cambridge CB2 3EJ, UK. National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA 94720-3370, USA.
Judith M FonvilleCenter for Pathogen Evolution, Department of Zoology, University of Cambridge, Downing Street, Cambridge CB2 3EJ, UK. World Health Organization (WHO) Collaborating Center for Modeling, Evolution, and Control of Emerging Infectious Diseases, Cambridge CB2 3EJ, UK. Department of Viroscience, Erasmus MC, Rotterdam 3015 GE, Netherlands.
Gregory D GromowskiNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Jose Bustos ArriagaNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Angela GreenDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA 94720-3370, USA.
Sarah L JamesCenter for Pathogen Evolution, Department of Zoology, University of Cambridge, Downing Street, Cambridge CB2 3EJ, UK. World Health Organization (WHO) Collaborating Center for Modeling, Evolution, and Control of Emerging Infectious Diseases, Cambridge CB2 3EJ, UK.
Louis LauDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA 94720-3370, USA.
Magelda MontoyaDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA 94720-3370, USA.
Chunling WangDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA 94720-3370, USA.
Laura A VanBlarganNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Colin A RussellDepartment of Veterinary Medicine, University of Cambridge, Cambridge CB3 0ES, UK.
Hlaing Myat ThuDepartment of Medical Research, Ziwaka Road, Yangon, Myanmar.
Theodore C PiersonNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Philippe BuchyInstitut Pasteur in Cambodia, Réseau International des Instituts Pasteur, Phnom Penh 12201, Cambodia.
John G AaskovInstitute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane 4001, Australia. Australian Army Malaria Institute, Brisbane 4051, Australia.
Jorge L Muñoz-JordánDengue Branch, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, San Juan 00971, Puerto Rico.
Nikos VasilakisDepartment of Pathology and Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX 77555, USA. Center for Tropical Diseases, University of Texas Medical Branch, Galveston, TX 77555, USA. Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX 77555, USA.
Robert V GibbonsDepartment of Virology, Armed Forces Research Institute of Medical Sciences, Bangkok 10400, Thailand.
Robert B TeshDepartment of Pathology and Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX 77555, USA. Center for Tropical Diseases, University of Texas Medical Branch, Galveston, TX 77555, USA. Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX 77555, USA.
Albert D M E OsterhausDepartment of Viroscience, Erasmus MC, Rotterdam 3015 GE, Netherlands.
Ron A M FouchierDepartment of Viroscience, Erasmus MC, Rotterdam 3015 GE, Netherlands.
Anna DurbinCenter for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
Cameron P SimmonsOxford University Clinical Research Unit, Wellcome Trust Major Overseas Programme, Ho Chi Minh City, Vietnam. Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX3 7LJ, UK. Department of Microbiology and Immunology, University of Melbourne, Parkville 3010, Australia.
Edward C HolmesMarie Bashir Institute for Infectious Diseases and Biosecurity, Charles Perkins Centre, School of Biological Sciences and Sydney Medical School, The University of Sydney, Sydney 2006, Australia.
Eva HarrisDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA 94720-3370, USA.
Stephen S WhiteheadNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Derek J SmithCenter for Pathogen Evolution, Department of Zoology, University of Cambridge, Downing Street, Cambridge CB2 3EJ, UK. World Health Organization (WHO) Collaborating Center for Modeling, Evolution, and Control of Emerging Infectious Diseases, Cambridge CB2 3EJ, UK. Department of Viroscience, Erasmus MC, Rotterdam 3015 GE, Netherlands. djs200@cam.ac.uk.
Funding
T Cell Responses Following DENV Natural Infections and Live-Attenuated Dengue Virus VaccinationP01AI106695 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI Timothy Patrick Sheahan · 2015 to 2026
$34.1MLaboratory And Preclinical Studies Of FlavivirusesZIAAI000891 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI WHITEHEAD, STEPHEN · 2009 to 2025
$17.5MNIH Director's Pioneer Award:Antigenic Cartography (RMI)DP1OD000490 · OD · UNIVERSITY OF CAMBRIDGE · PI SMITH, DEREK JAMES · 2005 to 2009
$2.6MEpidemiological, Clinical & Immunological Studies of Zika, dengue and chikungunyaR01AI099631 · NIAID · SUSTAINABLE SCIENCES INSTITUTE · PI BALMASEDA, ANGEL LAZARO · 2012 to 2021
$1.8MAnalysis of the neutralizing antibody response following flavivirus infectionZIAAI001022 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI PIERSON, THEODORE · 2009 to 2016
$1.7MIntramural NIH HHS Z99 AI999999Medical Research Council MR/K021885/1NIAID NIH HHS HHSN266200700010CNIAID NIH HHS HHSN272201000040INIAID NIH HHS HHSN272201400008CNIAID NIH HHS P01 AI106695NIAID NIH HHS R01 AI099631NIH HHS DP1 OD000490NIH HHS DP1-OD000490-01PHS HHS HHSN272201000040I/HHSN27200004/D04Wellcome Trust 089276Wellcome Trust 100891
Abstract
The four genetically divergent dengue virus (DENV) types are traditionally classified as serotypes. Antigenic and genetic differences among the DENV types influence disease outcome, vaccine-induced protection, epidemic magnitude, and viral evolution. We characterized antigenic diversity in the DENV types by antigenic maps constructed from neutralizing antibody titers obtained from African green monkeys and after human vaccination and natural infections. Genetically, geographically, and temporally, diverse DENV isolates clustered loosely by type, but we found that many are as similar antigenically to a virus of a different type as to some viruses of the same type. Primary infection antisera did not neutralize all viruses of the same DENV type any better than other types did up to 2 years after infection and did not show improved neutralization to homologous type isolates. That the canonical DENV types are not antigenically homogeneous has implications for vaccination and research on the dynamics of immunity, disease, and the evolution of DENV.
Indexed as
AnimalsAntibodies, NeutralizingAntibodies, ViralAntigens, ViralChlorocebus aethiopsDengue VaccinesDengue VirusEvolution, MolecularHumansImmune SeraPhylogenySerogroupSerotypingVaccinationViral Envelope ProteinsAntibodies, NeutralizingAntibodies, ViralAntigens, ViralDengue VaccinesE protein, Dengue virus type 3E protein TH Sman, Dengue virusglycoprotein E, dengue virus type 4Immune SeraViral Envelope Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.